The Alteco LPS adsorber is a medical device for extracorporeal removal of endotoxin during hemoperfusion.

The biotechnology of the product is based on a synthetic tailor-made peptide that selectively and irreversibly binds several times the endotoxin load found in patients with severe sepsis. The peptide covers the surface of a porous polymer matrix, specially designed to provide an optimal surface for the peptide rather than act as a filter.

Porexp president and CEO William Midgette noted the company strives to create innovative solutions that solve the specific challenges of its healthcare customers.

"Our research scientists and engineers are dedicated to delivering breakthrough innovations that provide next generation performance for our customer’s products," Midgette added.

Alteco Medical president Jonas Jonmark noted sepsis causes more deaths each year than prostate cancer, breast cancer and HIV/AIDS combined.

"Experts believe that sepsis is actually responsible for most deaths attributed to HIV/AIDS, malaria, pneumonia and other infections acquired in the community, in healthcare settings or by traumatic injury," Jonmark added.